Group Compassionate Mind Training for Adults Experiencing the Menopause Transition

What this trial studies

Menopause transition occurs naturally for women aged 45-55. In addition to the hormone changes, there are often changes in other areas of life including low mood, anxiety, 'brain fog' and embarrassment. Some people may not be eligible for or want to receive hormone replacement therapy, therefore psychological treatments for menopause have been investigated. There is growing evidence for the use of Compassionate Mind Training (CMT).

Conditions in scope

• Menopause

Interventions

• Compassionate Mind Training (Other) — Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.

Who can join

Women only · Ages 40 Years to 60 Years · Accepts healthy volunteers.

Inclusion criteria

• Adults (aged 40-60) who are biologically female
• Women who are experiencing symptoms of the menopause or peri-menopause; which is naturally occurring. This is identified through the STRAW criteria. Individuals have to answer Yes on at least one of the STRAW screening questions to ensure women are in the perimenopause or menopausal period.
• Substantial English verbal communication and comprehension skills
• Capacity to consent
• Confident in using video conferencing applications (MsTeams)
• Willingness to take part in a post-intervention interview about their experience.
• PHQ-9 score 5-19 (mild to moderate clinical cut offs)
• GAD-7 score 5-15 (mild to moderate clinical cut offs)

Exclusion criteria

• People under the age of 40
• People currently receiving any form of psychology intervention.
• Transgender females who are biologically male
• More than 5 years post menopause.
• PHQ-9 score greater or equal to 20 (severe clinical cut off)
• GAD-7 score greater or equal to 15 (severe clinical cut off)

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Interventional
• Phase: N/A
• Start date: 2024-06-20
• Primary completion: 2025-10-23
• Last update posted: 2026-05-07
• First posted: 2024-06-17

Sponsor & contact

Lead sponsor: University College, London (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• The Revised Women's Health Questionnaire (To be completed within one week before and within one week after the intervention)
  Measures health-related quality of life by measuring perceptions of physical and emotional experiences of middle-aged women. All subscales are scored from yes, definitely (1) to no, not at all (4) with subscales scored with a scoring algorithm transforming each score to a 0-100 scale.
• 36-Item Short Form Survey (To be completed within one week before and within one week after the intervention)
  Measures quality of life. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
• The Menopause Representations Questionnaire (MRQ) (To be completed within one week before and within one week after the intervention)
  Measure to assess beliefs about menopause. It consists of 20 items, scored either no (0), uncertain (1) or yes (2). Higher scores indicate more beliefs about the menopause.
• Fears of Compassion Scale (To be completed within one week before and within one week after the intervention)
  Measures fears of compassion. It has 38 items, scored either dont agree at all (0) to completely agree (4) on a Likert scale. There are three subscales, subscale items are summed, with higher scores indicating higher fears of compassion.
• Patient Health Questionnaire-9 (PHQ-9) (To be completed within one week before and within one week after the intervention)
  Measures severity of depression. Score from 0-27, higher scores represent higher severity of symptoms of depression.

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.